ライフサイエンスコーパス: systemic candidiasis

1 like pathogen and can cause life-threatening systemic candidiasis.

2 gal control that influences host survival in systemic candidiasis.

3 1-M280 was associated with increased risk of systemic candidiasis.

4 e (PE), and is avirulent in a mouse model of systemic candidiasis.

5 n and promotes virulence in a mouse model of systemic candidiasis.

6 es remain the "gold standard" for diagnosing systemic candidiasis.

7 , and it was avirulent in the mouse model of systemic candidiasis.

8 attenuated for virulence in a mouse model of systemic candidiasis.

9 have a protective role in host resistance to systemic candidiasis.

10 eractions was evaluated in a murine model of systemic candidiasis.

11 nistic pathogen that causes mucosal and deep systemic candidiasis.

12 cans, using immunocompetent murine models of systemic candidiasis.

13 mmune cells, are particularly susceptible to systemic candidiasis.

14 s of CAP1 were avirulent in a mouse model of systemic candidiasis.

15 e mouse model of hematogenously disseminated systemic candidiasis.

16 ponsible for about 15 percent of mucosal and systemic candidiasis.

17 resistance to gastric, anorectal, and acute systemic candidiasis.

18 to establish infection in a murine model of systemic candidiasis.

19 allenge contribute to protective immunity to systemic candidiasis.

20 nd euthymic bg/bg-nu/+ mice from mucosal and systemic candidiasis.

21 ation and phagocytosis and protect mice from systemic candidiasis.

22 creases susceptibility of mice and humans to systemic candidiasis.

23 r of immune defense against both mucosal and systemic candidiasis.

24 gus Candida albicans is the leading cause of systemic candidiasis, a disease with poor prognosis affe

25 Candida albicans is the leading cause of systemic candidiasis, a fungal disease associated with h

26 ht represent an accurate and early marker of systemic candidiasis, a hypothesis that should be tested

27 Systemic candidiasis affects 1.6 to 4.5% of very low bir

28 role of this cytokine in the pathogenesis of systemic candidiasis are not well understood.

29 y to secrete IL-17 are highly susceptible to systemic candidiasis, but we found that temporary blocka

30 Overall, our results indicate that systemic candidiasis can develop in the absence of HR, b

31 pha plays a key role in host defense against systemic candidiasis caused by either C. glabrata or C.

32 he hyperresistance of IL-10 KO mice to acute systemic candidiasis did not seem to correlate with nitr

33 ida albicans antigens among 60 patients with systemic candidiasis due to various Candida spp. and 24

34 ct is considered a major portal of entry for systemic candidiasis, experiments were designed to clari

35 ffect on the early, innate response to acute systemic candidiasis; however, in comparison to immunoco

36 part of the normal flora but it also causes systemic candidiasis if it reaches the bloodstream.

37 Using the simplified model, we predicted systemic candidiasis in a separate test sample of 32 pat

38 f URA3 contributed to the severity of murine systemic candidiasis in BALB/c mice.

39 The incidence of systemic candidiasis in bg/bg-nu/nu mice was significant

40 Previous evaluation of HWP1 in systemic candidiasis in CBA/J mice was done with Candida

41 Antifungal prevention of systemic candidiasis in immunocompetent critically ill a

42 al cells and had a reduced capacity to cause systemic candidiasis in mice.

43 During murine systemic candidiasis, interruption of CCR2-dependent inf

44 were orally immunized mice more resistant to systemic candidiasis (intravenous challenge) than were g

45 Systemic candidiasis is a major cause of complicating in

46 an antimannan antibody in host resistance to systemic candidiasis is influenced by its IgG subclass.

47 Therefore, the role of farnesol in systemic candidiasis is likely due to its ability to inh

48 Furthermore, in a model of systemic candidiasis, mice lacking group V sPLA(2) had a

49 In a murine acute systemic candidiasis model, C albicans strongly stimulat

50 yphal formation and decreases virulence in a systemic candidiasis model, suggesting a role for post-t

51 l of mice, decreased severity of mucosal and systemic candidiasis, modulation of immune responses, de

52 he beta2m-/- mutant mice were susceptible to systemic candidiasis of endogenous origin despite the in

53 No deaths or systemic candidiasis of endogenous origin were evident i

54 role of phagocytic cells during mucosal and systemic candidiasis of endogenous origin.

55 or 4 weeks showed any histologic evidence of systemic candidiasis of endogenous origin.

56 their natural susceptibility to mucosal and systemic candidiasis of endogenous origin.

57 cient to protect J(H)D mice from mucosal and systemic candidiasis of endogenous origin; however, func

58 s variant extended the survival of mice with systemic candidiasis (P < 0.001).

59 Studies using animal models of systemic candidiasis pointed to possible differences in

60 The crude mortality rate among neonates with systemic candidiasis remains approximately 30%.

61 andidiasis of endogenous origin and to acute systemic candidiasis (resulting from intravenous injecti

62 In vivo efficacy studies in a mouse model of systemic candidiasis showed that AM2 (5) successfully cu

63 rom the kidney of antibody-treated mice with systemic candidiasis showed uniform binding of each vari

64 ere significantly higher among patients with systemic candidiasis than among controls, whereas IgM re

65 IL-4 cytokine gene were more susceptible to systemic candidiasis than were immunocompetent controls.

66 a coli cells both ex vivo and in vivo During systemic candidiasis, the absence of alphaXbeta2 resulte

67 Here, using a mouse model of systemic candidiasis, we found that resident macrophages

68 In contrast to systemic candidiasis, we observed no significant (P < 0.

69 ge IL-12, are critical to resistance against systemic candidiasis, while Th2 cytokines such as IL-4 a

70 ediction model that identified patients with systemic candidiasis with an error rate of 3.7%, a sensi

71 ction with a well-established mouse model of systemic candidiasis with C. albicans A72 administered b